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Abstract  
Lung  cancer  is  the  leading  cause  of  cancer  related  death  worldwide,  reflecting  an  unfortunate  
combination  of  very  high  prevalence  and  low  survival  rates,  as  most  cases  are  diagnosed  at  
advanced  stages  when  treatment  efficacy  is  limited.  Lung  cancer  comprises  several  disease  
groups   with   non-­small   cell   lung   cancer   (NSCLC)   accounting   for   ~85%   of   cases   and   lung  
adenocarcinoma  being  its  most  frequent  histological  subtype.  Mutations  in  KRAS  affect  ~30%  
of   lung   adenocarcinomas   but   unlike   other   commonly   altered   proteins   (EGFR   and   ALK,  
affected   in   ~14   and   7%   of   cases,   respectively),   mutant   KRAS   remains   untargetable.  
Therapeutic  strategies  that  rely  instead  on  the  inhibition  of  mutant  KRAS  functional  output  or  
the  targeting  of  mutant  KRAS  cellular  dependencies  (i.e.  synthetic  lethality)  are  an  appealing  
alternative  approach.  Recent  studies   focused  on   the  metabolic  properties  of  mutant  KRAS  
lung   tumours   have   uncovered   unique  metabolic   features   that   can   potentially   be   exploited  
therapeutically.  We  review  these  findings  here  with  a  particular  focus  on  in  vivo,  physiologic,  
mutant  KRAS  activity.  
Cancer  metabolism:  the  general  picture  
The  reprogramming  of  cellular  metabolism  is  now  a  widely  recognised  hallmark  of  cancer  [1],  
involving  a  complex  rearrangement  of  metabolic  and  energy  producing  networks  to  support  
the  high  proliferation  rate  of  tumour  cells  and  their  unique  metabolic  demands.  Arguably,  the  
most   striking   and   well-­characterised  metabolic   feature   of   tumours   is   their   altered   glucose  
metabolism.  In  the  1920s,  Otto  Warburg  showed  that  tumour  cells  exhibit  an  enhanced  avidity  
for  glucose,  a  critical  cell  nutrient,  compared  to  normal  tissue  [2]  and  this  metabolic  phenotype  
has  since  been  confirmed  in  a  large  proportion  of  tumours.  In  fact,  it  is  routinely  exploited  in  
the  clinic  to  both  diagnose  and  stage  tumours  through  positron  emission  tomography  (PET)-­
based  tumour  imaging,  which  relies  on  the  enhanced  uptake  of  a  radioactive  fluorine-­labelled  
glucose  analogue  (18F-­fluorodeoxyglucose)  by  tumour  cells,  relative  to  normal  tissue  [3].    
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Warburg  also  noted  that  under  aerobic  conditions,  conversion  of  glucose  to  lactate  (aerobic  
glycolysis)  is  significantly  more  prevalent  in  tumour  cells  than  in  normal  ones.  Furthermore,  
he  argued  that  tumour  cells  rely  more  on  aerobic  glycolysis  to  metabolise  glucose  than  on  the  
more   energy   efficient   process   of   mitochondrial   oxidative   phosphorylation,   preferentially  
utilised  by  normal  cells  [2].  This  glycolytic  switch,  known  as  the  “Warburg  effect”,  was  initially  
described  as  a  compensation  mechanism  for  mitochondria  dysfunction  in  tumours  [4],  but  its  
causes  are  now  thought  to  be  more  complex.  While  mitochondrial  damage  can  contribute  to  
this  metabolic  rewiring,  mitochondria  remain  functional  in  the  majority  of  tumours,  but  aerobic  
glycolysis   is  nevertheless  observed   in  such  cases.   Instead,  glucose  metabolism  rewiring   is  
more  likely  driven  by  the  high  demand  of  cancer  cells  for  reducing  equivalents  and  molecular  
precursors  of  proteins,  lipids  and  nucleotides,  the  “building  blocks”  required  to  maintain  their  
enhanced  growth  and  proliferation  [5].    
Multiple  additional  metabolic  changes  have  since  been  reported  in  cancer  cells  including  the  
reprogramming  of  amino  acid  metabolism  (to  supplement  the  tricarboxylic  acid  (TCA)  cycle  as  
well   as   amino   acid   and   nucleotide   biosynthesis);;   and   altered   lipid  metabolism   (to   support  
increased  membrane  synthesis  and  provide  energy  storage)  [6-­8].  The  rewiring  of  glucose,  
amino   acid   and   lipid   metabolism   can   also   alter   cell   signalling   and   oxidative   stress  
management   [9].   Reactive   oxygen   species   (ROS)   are   a   natural   by-­product   of   oxygen  
metabolism  [10]  and  can  have  an  important  impact  on  cell  fate.  ROS  are  generated  through  
both  enzymatic  and  non-­enzymatic  reactions  in  the  mitochondria,  endoplasmic  reticulum  and  
peroxisomes  and  can  also  be  produced  by  exogenous  sources.  High  ROS  levels  are  toxic  to  
cells   and   therefore,   in   normal   cells,   ROS   production   (e.g.   by   the   respiratory   chain)   and  
scavenging   (e.g.   through   glutathione   and   superoxide   dismutases)   are   tightly   regulated   to  
ensure  survival  [11].    
Nevertheless,  at  well-­tolerated  levels,  ROS  can  act  as  intracellular  signalling  molecules  and  
play  important  regulatory  roles,  potentially  providing  selective  advantages  to  cells  [9,  12-­17].  
Cancer  cells  frequently  display  increased  ROS  levels  but  their  role  in  tumourigenesis  remains  
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controversial.   Persistent  ROS  exposure  was   reportedly   associated  with  DNA  damage  and  
predisposition  to  cancer  [18].  However,  attempts  to  treat  tumours  with  antioxidants  have  been  
largely  unsuccessful  and   there   is  evidence   that   they  can   in   fact  promote  cancer   in   certain  
contexts  [19].  In  agreement,  recent  studies  suggest  that  tumours  frequently  exhibit  enhanced  
antioxidant   capacity   and   that   this   phenotype   may   be   positively   selected   during   tumour  
development  [20-­22]. 
The   general   picture   of   cancer   metabolism   reprogramming   is   thus   one   of   complex  
rearrangements   where   contradictions   abound.   Part   of   the   difficulty   in   interpreting   these  
changes  derives  from  attempts  to  generalise  observations  acquired  under  defined,  and  often  
artificial   conditions.   While   most   cancers   undergo   metabolic   rewiring,   mounting   evidence  
suggests   that   tumour  metabolism  signatures  are  context  dependent,  being   influenced  by  a  
wide  range  of  factors  including  oncogenic  signalling,  tissue  of  origin,  microenvironment  and  
tumour   grade   [21,   23-­25].   Tumour   type   specific   in   vivo   analyses   of   metabolism   are   thus  
fundamental  to  the  improved  understanding  of  their  metabolic  rewiring.    
NSCLC  metabolism:  an  in  patient  perspective    
Advances  in  technology  are  now  providing  unique  opportunities  to  study  metabolic  fluxes  in  
situ.   Through   the   combined   use   of   13C-­labelled   substrate   infusions   in   tissues   and  
comprehensive   profiling   of   carbon   flux   by  metabolomics   analysis   [26]   Fan   and   colleagues  
were  able   to  demonstrate  metabolic   rewiring   in   fresh  NSCLC  surgical   resections  of  mixed  
histology   [27].   These   lung   tumours   showed   increased   levels   of   lactate,   demonstrating   the  
expected  increase  in  glycolysis  relative  to  normal  tissue.  Tumour  samples  also  exhibited  an  
increase  in  glucose-­derived  TCA  cycle  intermediates,  such  as  citrate  and  succinate,  indicating  
that  TCA  cycle  activity  is  enhanced  in  NSCLC  relative  to  normal  lung.  
Typically,  glycolysis   is   linked   to   the  TCA  cycle  by   the  activity  of  pyruvate  dehydrogenases,  
which  mediate  the  conversion  of  pyruvate  (the  output  of  glycolysis)  to  Acetyl-­CoA,  that  then  
enters  the  TCA  cycle.  Fan  and  colleagues  reported  that  an  alternative  TCA  cycle  entry  route,  
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mediated   by   pyruvate   carboxylase   activity,  was   upregulated   in  NSCLC  samples.  Pyruvate  
carboxylase   catalyses   the   irreversible   carboxylation   of   pyruvate   to   oxaloacetate,   a   TCA  
metabolite  that  is  also  utilized  in  biosynthetic  reactions.  Pyruvate  carboxylase  activity  allows  
TCA  cycle  replenishment  of  oxaloacetate  whenever  its  levels  are  reduced  due  to  biosynthetic  
reactions  (anaplerosis)  [27],  and  its  enhanced  activity  may  play  an  important  role  in  fulfilling  
the  high  anabolic  demands  of   these   tumours.  The  anaplerotic  metabolism  of  pyruvate  was  
also  observed  in  early-­stage  NSCLC  tissue  and  lung  cancer  slices  ex  vivo  [28]  (i.e.  “Warburg  
slice”  method  [29]).  Furthermore,  knockdown  of  pyruvate  carboxylase  in  NSCLC  cells  resulted  
in  decreased  tumour  growth  in  a  xenograft  model,  suggesting  a  dependence  of  lung  tumours  
on  pyruvate  carboxylase-­dependent  anaplerosis   [28].  Together,   these  studies  demonstrate  
that   the   reprogramming   of   glucose   metabolism   in   lung   cancers   involves   both   an   aerobic  
glycolytic  switch  and  the  channelling  of  glucose-­derived  metabolites  through  the  TCA  cycle  
(Figure  1).    
Through  combined  multimodal   imaging  analysis  and  13C-­glucose  flux  profiling  of  NSCLC   in  
situ,  Hensley  and  colleagues  independently  confirmed  the  enhancement  of  glycolysis,  TCA  
cycle   activity   and   pyruvate   carboxylation   in   tumour   tissue   relative   to   normal   lung   [23].  
Increased  activity  of  pyruvate  dehydrogenase  was  also  reported  and  shown  to  contribute  to  
enhanced   glucose   oxidation   across   different   histological   tumour   subtypes   (Figure   1).  
Strikingly,   this   study  uncovered  a  high  degree  of   glucose  metabolism  heterogeneity  within  
NSCLC,  both  between  and  within   tumours.  The  authors  showed   that   tissue  perfusion   (low  
versus   high,   as   determined   by   tumour   vasculature   status),   dictated   preferential   nutrient  
utilization  in  a  given  region,  as  well  as  its  metabolic  profile.  Accordingly,  areas  of  low  perfusion  
preferentially  utilized  glucose,  while  highly  perfused  regions  relied  more  on  other  nutrients.  
These  data  suggest  a  role  for  the  tumour  microenvironment  on  the  metabolic  heterogeneity  of  
lung  tumours,  as  recently  reported  for  mouse  models  of  pancreatic  cancer  [30-­32].  
Overall,  the  abovementioned  studies  provide  strong  evidence  of  metabolic  rewiring  in  NSCLC.  
However,  they  show  that  in  lung  tumours,  metabolic  rewiring  is  defined  by  common  tumour  
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features,  but  also  by  a  high  degree  of  intra  and  inter-­tumour  heterogeneity.  From  patient  data  
it   is   unclear   whether   other   factors,   besides   tissue   perfusion,   can   contribute   to   NSCLC  
metabolic  heterogeneity.  Given  that  lung  cancers  exhibit  a  high  mutation  burden  [33,  34],  it  is  
possible  that   their  genetic  heterogeneity   is  also  reflected  at   the  metabolic   level,  particularly  
since  oncogene  activation  and  loss  of  tumour  suppressors  can  alter  cellular  metabolism  [12].  
Interestingly,  Hensley  and  colleagues  reported  similar  metabolic  profiles  in  lung  tumours  with  
distinct   driver  mutations   (KRAS,  EGFR  or   no   known  driver)   [23].  However,   the   number   of  
tumours  analysed  for  each  group  was  relatively  small,  potentially  preventing  the  detection  of  
mutation-­specific  signatures.  Mouse  models  can  overcome  these  sample  limitations  and  are  
therefore  a  powerful  tool  to  address  the  relative  impact  of  specific  lung  cancer  mutations  on  
tumour  metabolism.  	  
Mutant  Kras  lung  adenocarcinoma:  from  man  to  mouse  
KRAS  (V-­Ki-­ras2  Kirsten  rat  sarcoma  viral  oncogene  homolog)  is  the  most  frequently  mutated  
oncogene  in  lung  adenocarcinoma  and  a  member  of  the  RAS  family  of  GTPases,  which  also  
includes  HRAS  and  NRAS   [33,  35,  36].  KRAS   is  activated   through  GTP  binding  and  once  
GTP-­bound,  can  trigger  multiple  signalling  transduction  pathways  and  impact  a  wide  range  of  
cellular   processes,   including   proliferation,   cell   survival   and   metabolism.  KRAS   is   typically  
mutated  in  human  cancer  through  missense  mutations  on  codons  12,  13  and  61  that  alter  its  
protein  conformation,  resulting  in  the  accumulation  of  constitutively  active,  GTP-­bound  KRAS  
protein  [36,  37].    
KRAS  mutations  are  highly  prevalent  in  NSCLC,  being  present  in  approximately  one  third  of  
lung   adenocarcinomas   [33,   38,   39].   However,   while   in   other   tumour   types   (e.g.   colorectal  
cancer)   KRAS   mutations   were   directly   linked   to   patient   survival   [40,   41],   the   prognostic  
relevance  of  KRAS  mutations  in  NSCLC  is  unclear  [42],  highlighting  our  lack  of  understanding  
of  the  oncogenic  impact  of  these  mutations  in  lung  cancer.  The  development  of  mutant  Kras  
lung  tumour  mouse  models  [43-­46]  helped  define  Kras  mutations  as  oncogenic  drivers  in  lung  
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adenocarcinoma.   Indeed,   independent   groups   showed   that   the   activation   of   a   single,  
endogenously   regulated   mutant   Kras   allele   (KrasG12V   [44];;   KrasG12D   [43])   is   sufficient   to  
promote   lung   tumour   initiation   (adenoma)   in   mice.   Additional   mutations   are   nevertheless  
required   to   promote   the   development   of   lung   adenocarcinoma.   This   progression   can   be  
accelerated   in   these  models   by   combining   two  most   frequent   genetic   alterations   found   in  
human   lung  adenocarcinoma  [33]:  mutant  Kras  activation  and  Trp53  (p53)   inactivation/loss  
[47].  
Mutant   Kras-­driven   lung   tumour  mouse  models   are   widely   used   in  mechanistic   studies   of  
tumour  development  and  pre-­clinical  trials,  for  their  ability  to  closely  recapitulate  the  human  
disease.  Since  lung  lesions  from  Krasmutant;;p53-­/-­  mice  progress  rapidly,  this  genetic  model  is  
frequently  used   to  study   lung  adenocarcinoma  phenotypes.   In  contrast,   lung   tumours   from  
mutant   Kras   mice   (that   retain   wild-­type   p53)   typically   only   mimic   early   disease   stages  
(hyperplasias,   adenomas).   If   allowed   to   age,   these   lesions   can   nevertheless   evolve   to  
adenocarcinomas,  at  which  stage  p53  is  frequently  inactive  [43,  46,  47].  Given  that  p53  can  
have  a  major  impact  on  cellular  metabolism  (e.g.  it  can  inhibit  glucose  uptake  and  glycolysis,  
promote   mitochondrial   respiration,   regulate   oxidative   stress)   [48,   49],   the   metabolic  
distinctions  between  these  models  are  potentially  significant  and  should  be  considered  in  the  
interpretation  of  mutant  Kras  lung  tumour  metabolic  findings  derived  from  distinct  models.      
The   progression   of   mutant   Kras-­driven   murine   lung   tumours   to   adenocarcinoma   can   be  
accelerated  by  alternative  cooperating  mutations,  namely  loss  of  the  Liver  kinase  B1  (Lkb1,  
also  known  as  Stk11)  [50,  51].  Lkb1  mediates  mTOR  signalling  via  activation  of  AMPK  (AMP-­
activated  protein  kinase),  a  key  metabolic  sensor  [52-­55].  Hence,  similarly  to  p53,  Lkb1  loss  
can  have  a  direct  effect  on   the  metabolic  phenotypes  of  mutant  Kras   tumours.  The  use  of  
different   variations   of   these   and   other   murine   models   is   enabling   the   identification   of   the  
metabolic  changes  that  mutant  Kras  lung  tumours  undergo  during  their  development,  and  their  
potential  therapeutic  implications.  
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Metabolic  rewiring  in  murine  mutant  Kras  lung  tumours    
Mutant  Kras  activity  leads  to  increased  proliferation  in  multiple  modelling  systems  both  in  vitro  
and   in   vivo.   Thus,   unsurprisingly,   mutant   Kras   cancer   cells   exhibit   metabolic   signatures  
typically   associated   with   high   energetic   and   anabolic   needs,   including   enhanced   nutrient  
uptake   and   rewiring   of   their   metabolism,   as   well   as   increased   autophagy   and  
macropinocytosis,  relative  to  non-­mutant  cells  [36,  56].  Glucose  metabolic  flux  analysis  carried  
out  independently  by  different  groups  revealed  clear  similarities  between  mutant  Kras;;p53-­/-­  
murine  lung  adenocarcinomas  [21,  57]  and  human  NSCLC  metabolism  [23,  27,  28],  confirming  
the   relevance   of   these  autochthonous  murine  models   for   the   study   of   human   lung   cancer  
metabolism.   Among   these   shared   phenotypes   are   enhanced   glucose   uptake   and   its  
processing  through  glycolysis  and  the  TCA  cycle  (Figure  2).  Crucially,  murine  models  are  also  
uncovering  novel  metabolic  properties  of  mutant  Kras  lung  tumours,  as  well  as  new  layers  of  
metabolic  heterogeneity.  These  findings  are  summarised  below.    
•   Amino  acid  utilization  
Multiple  in  vitro  studies  suggest  a  major  role  for  glutamine  utilization  in  cancer  metabolism.  In  
agreement,  human  pancreatic  ductal  adenocarcinoma  (PDAC)  cell   lines  and  subcutaneous  
xenograft  models  were   shown   to   rely   on  glutamine  metabolism   rewiring   to  maintain   redox  
balance.  In  these  models  glutamine  derived  aspartate  was  converted  into  oxaloacetate  (in  an  
aspartate   transaminase-­dependent  manner),  which  was   then   further  processed   into  malate  
and  pyruvate,  increasing  the  NADPH/NADPH+  ratio  in  cells  [58].  To  what  extent  spontaneous  
PDAC  may  rely  on  this  metabolic  rewiring  is  however  unclear.    
However,  unlike  the  majority  of  tumour  cells  grown  in  culture  and  PDAC  xenografts  [56,  58,  
59],  glutamine  utilization  was  shown  to  be  minimal  in  murine  p53-­/-­;;KrasG12D  lung  tumours  and  
not   increased   relative   to   normal   lung   tissue   [57].   These   data   are   consistent   with   human  
NSCLC  findings,  where  no  preferential  glutamine  utilization  was  observed  in  tumours  relative  
to  the  surrounding  lung  [28].  These  data  indicate  that  glutamine  is  not  a  major  contributor  to  
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lung   cancer   metabolism.   Moreover,   these   findings   emphasize   the   relevance   of   in   vivo,  
autochthonous   models   for   the   study   of   tumour   phenotypes   and   suggest   that   metabolic  
signatures  identified  in  vitro  may  fail  to  recapitulate  in  vivo  phenotypes.  These  discrepancies  
are  likely  due  to  the  effects  of  tissue  culture  stress,  non-­physiological  levels  of  nutrients  and  
absence  of  tumour  cell  extrinsic  factors  (e.g.  tumour  microenvironment)  in  these  cultures.    
Amino  acid  metabolism  is  nevertheless  altered  in  KrasG12D/+;;p53-­/-­  lung  tumours.  In  particular,  
increased  uptake  of  branched-­chain  amino  acids  was  observed   in   these  adenocarcinomas  
and  conversely,   lung  tumour  bearing  animals  exhibited  decreased  levels  of  branched-­chain  
amino  acids  in  their  plasma  [25].  Branched-­chain  amino  acids,  such  as  leucine  and  valine,  are  
involved  in  multiple  metabolic  and  cellular  processes,  and  flux  analysis  in  KrasG12D/+;;p53-­/-­  lung  
tumours  demonstrated  their  utilization  in  tissue  protein  biosynthesis  and  as  a  nitrogen  source  
(Figure  2).  Depletion  of  the  branched-­chain  amino  acid  transaminase  Bcat1  and  Bcat2  genes  
impaired  the  ability  of  lung  tumour  cell  lines  to  form  subcutaneous  and  orthotopic  tumours  in  
recipient  mice,  suggesting  that  branched-­chain  amino  acid  transamination  is  required  for  lung  
tumour   development.   Interestingly,   these   phenotypes  were   not   recapitulated   in   pancreatic  
tumours  driven  by  the  same  oncogenic  drivers,  providing  direct  evidence  of  tumour  specificity  
regarding  metabolic  dependences.    
•   Lipid  biosynthesis  and  b-­oxidation  
In  vivo  models  indicate  that  lipid  metabolism  plays  an  important  role  in  the  development  and  
maintenance  of  mutant  Kras   lung   tumours.  Acyl-­coenzyme  A   (CoA)   synthetase   long-­chain  
family  member  3  (Acsl3)  plays  a  key  role  in  lipid  metabolism  by  converting  fatty  acids  into  fatty  
Acyl-­CoA   esters,   the   substrates   for   lipid   synthesis   and   β-­oxidation.   Acsl3   was   found  
upregulated  in  mutant  Kras  tumours  (Tet-­op-­KrasG12D  model  [60])  compared  to  normal   lung  
tissue,  and   is  also  highly  expressed   in  human   lung  cancers   [61].  While  Acsl3-­loss  had  no  
deleterious   effects   on   normal   lung,   LSL-­KrasG12D;;Acsl3-­/-­   mice   showed   a   decrease   in   the  
number  of   lung   lesions,  and  the  ones  that   formed  were  more  benign  than  those  from  LSL-­
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KrasG12D  mice.  These  data  indicate  that  Acsl3  activity  is  important  for  mutant-­Kras  driven  lung  
tumour  initiation.      
Lipid  metabolism  was   also   enhanced   in   advanced  mutant   Kras   lung   tumours.   Deuterium-­
labelling   experiments   suggest   that   lung   adenocarcinomas   from   two   distinct   spontaneous  
mutant  Kras  models  (p53-­/-­  and  Lkb1-­/-­)  exhibit  high  levels  of  de  novo  fatty  acid  synthesis  [62]  
(Figure  2).  Moreover,  these  tumours  showed  a  high  dependence  on  Acetyl-­CoA  carboxylase,  
(the   rate   limiting   enzyme   for   fatty   acid   synthesis   [63])   for   their   maintenance.   Accordingly,  
genetic  depletion  and  pharmacological  inhibition  of    Acetyl-­CoA  carboxylase  inhibited  tumour  
growth   in  xenografts  and  autochthonous  murine   lung   tumour  models   (p53-­/-­;;KrasG12D/+;;  and  
Lkb1-­/-­;;KrasG12D/+)  [62].  
Autophagy   inhibition,   through   loss  of   the  autophagy  related  gene  7   (Atg7),  also  exposed  a  
potential  lipid  dependence  of  KrasG12D/+;;p53-­/-­  lung  tumours.  Autophagy  inhibition  had  a  major  
therapeutic  effect  in  this  model  by  blocking  tumour  growth,  inducing  cell  death,  and  converting  
existing   lesions   into   benign   oncocytomas   [64].   These   oncocytomas   exhibited   damaged  
mitochondria  and  lipid  accumulation,  suggestive  of  defective  fatty  acid  oxidation.  Interestingly,  
lipid  accumulation  was  only  seen  in  tumours  that  lacked  p53,  while  the  oncocytoma  phenotype  
was  also  observed  in  the  KrasG12D/+  model.  It  is  unclear  how  p53-­loss  may  contribute  to  this  
lipid  accumulation  or  if  disruption  of  oxidation  of  other  substrates  (i.e.  glucose)  contributed  to  
these  phenotypes.  Nevertheless,  these  data  show  a  differential  regulation  of  lipid  metabolism  
in   tumours   that   lack   p53,   which   are   typically   more   advanced,   suggesting   that   metabolic  
rewiring  may  co-­evolve  with  tumours.    
•   Glucose  metabolism  and  lung  tumour  progression  
As   discussed   above,   both   murine   and   human   lung   tumours   show   evidence   of   glucose  
metabolism  rewiring.  However,  our  lab  recently  showed  that  in  KrasG12D;;p53-­/-­  lung  tumours,  
glucose  metabolism  is  significantly  distinct  in  low  and  high  grade  lesions,  and  modulated  by  
mutant  Kras   allelic   content   [21].   These   data   imply   that   tumour   grade   and/or   mutant  Kras  
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content   can   significantly   contribute   to   the   metabolic   heterogeneity   of   mutant   Kras   lung  
tumours.  
As  lung  tumours  from  KrasG12D/+;;p53-­/-­  mice  progress  from  low  to  high  grade  they  frequently  
acquire  additional  copies  of  the  mutant  allele  (KrasG12D/Kraswild-­type  alleles  >  1).  Mutant  KRAS  
allelic  gains  are  also  frequent  in  human  lung  cancer  and  NSCLC  cell  lines.  Indeed,  ~49%  of  
mutant  KRAS  NSCLC  cell   lines  are  homozygous  for   the  mutant  copy  [21,  65,  66].  We  and  
others  previously  showed  that  these  mutant  gene  copy  gains  can  lead  to  p53  activation  and  
may  contribute  to  p53  counter-­selection   in   lung  cancer  (Figure  3)   [67,  68].  Our  recent  data  
show  that  these  copy  gains  also  affect  glucose  metabolism  and  redox  management.  Indeed,  
KrasG12D/G12D;;p53-­/-­  cells  showed  increased  expression  of  glycolytic  genes  and  altered  glucose  
metabolism  relative  to  KrasG12D/+;;p53-­/-­  cells.  Glucose  flux  analysis  revealed  that  homozygous  
mutant  Kras  cells  underwent  a  glycolytic  switch,  which  was  coupled  to  increased  channelling  
of  glucose-­derived  metabolites  into  the  TCA  cycle  and  towards  the  biosynthesis  of  glutathione  
[21],  a  key  cellular  antioxidant  [69]  (Figure  2  and  3).  A  similar  metabolic  rewiring  was  observed  
in  high  grade  lung  tumours,  which  acquire  extra  copies  of  mutant  Kras.  In  contrast,  low  grade  
tumours,   which   remain   heterozygous   for   mutant   Kras,   showed   a   similar   glucose-­derived  
carbon  flux  to  that  seen  in  normal  tissues,  providing  evidence  of  metabolic  rewiring  during  the  
malignant  progression  of  this  lung  tumour  model.  
Mutant  KRAS  content-­dependent  differences  in  glucose  metabolism  or   in  the  expression  of  
glycolytic  and  glutathione  biosynthesis  genes  were  also  observed   in  NSCLC  cell   lines  and  
human  lung  adenocarcinoma,  respectively  [21].  It  is  however  unclear  what  factors  drive  the  
selective  pressure  for  these  mutant  gains  or  the  resulting  metabolic  rewiring.  Murine  models  
showed   no   difference   in   the   proliferative   capacity   of   mutant   Kras   heterozygous   and  
homozygous  cells,  suggesting  that  other  factors  may  initially  promote  the  outgrowth  of  mutant  
Kras  homozygous  cells.  The  increased  antioxidant  capacity  of  homozygous  mutant  Kras  cells  
[21]  may  directly  contribute  to  their  selective  growth  during  lung  tumour  progression.  However,  
the  effects  of  ROS  on  lung  tumour  development  remain  somewhat  controversial,  as  discussed  
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below.  Extrinsic   factors,  such  as  presence/absence  of  particular  stromal  cells,  variations   in  
nutrient  availability   [23]  or  varying  oxygen   levels  within   the  growing  tumour  mass  may  also  
contribute   to   this   selection.   In   support   of   the   latter,   enhanced   expression   of   the   hypoxia-­
inducible  factor  Hif2a  (Hif2a  knock-­in)  promoted  tumour  growth  and  malignant  progression  of  
KrasG12D  lung  tumours  [70].    
ROS  management  in  mutant  Kras  lung  tumours  
Multiple  studies  have  shown  an  effect  of  Kras  mutations  on  ROS  management  in  vivo  but  the  
implications  of  these  effects  varied  depending  on  experimental  context.  On  one  hand,  it  has  
been  proposed  that  mutant  Kras  can  promote  ROS  generation  [71,  72].  A  pro-­tumourigenic  
effect   of   mutant   Kras-­mediated   ROS   induction   in   pancreatic   cells   was   also   proposed.  
Accordingly,   upregulation   of   mitochondrial   ROS   generation   by   endogenously   regulated  
KrasG12D   in   pancreatic   acinar   cells   was   shown   to   promote   the   formation   of   precancerous  
lesions   [73].   In   contrast,   DeNicola   and   colleagues   showed   that   endogenously   expressed  
mutant   Kras   can   reduce   oxidative   stress   through   the   induction   of   the   key   antioxidant  
programme  regulator  Nfe2l2  (Nrf2)  [22].  Furthermore,  Nrf2  loss  inhibited  the  development  of  
benign  lung  tumour  lesions  in  KrasG12D/+;;Nrf2-­/-­  mice,  demonstrating  that  the  antioxidant  activity  
of   this   gene   can   promote  mutant   Kras-­driven   lung   tumour   initiation.   Together,   these   data  
indicate   that   the   effects   of   mutant   Kras   on   ROS   production   are   tissue   specific;;   or   that  
oncogenic  Kras   regulates   redox  management   through  modulation  of  both  ROS  generation  
and  scavenging.  
In   support   of   a   lung   tumour   promoting   role   for   reducing   agents,   ROS   inhibition   through  
administration   of   the   antioxidants   N-­acetylcysteine   (NAC)   and   Vitamin   E   significantly  
enhanced  lung  tumour  burden  and  decreased  the  survival  of  (p53  wild-­type)  KrasG12D/+  mice  
[19].  NAC  and  Vitamin  E  treatment  contributed  to  lung  tumour  development  by  reducing  ROS,  
DNA  damage  and  promoting   tumour  proliferation  but   interestingly,   these   tumour  promoting  
effects  were  lost   in  p53-­/-­  mice.  The  authors  concluded  that  antioxidant  treatment  promoted  
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tumour   growth   by   preventing   p53-­mediated   anti-­proliferative   responses   [19].   It   is   however  
unclear  how  tumour  ROS  levels  were  affected  by  p53  loss  or  antioxidants  in  this  context.    
ROS  regulation  by  p53  is  complex  and  poorly  understood  in  the  context  of  mutant  Kras.  On  
one  hand  p53  can  promote  antioxidant  responses  through  different  mechanisms.  However,  
when  levels  of  damage  are  high,  p53  can  induce  a  pro-­oxidant  state  that  leads  to  cell  death  
[48].  Under  normal  conditions  inactivation  of  p53  can,  in  principle,  result  in  enhanced  ROS  but  
it  would  be  important  to  establish  to  what  extent  mutant  Kras  activity  may  modulate  this  effect  
in  lung  tumours.  The  enhanced  levels  of  the  glutathione  and  its  precursors  (glutamate,  serine  
and   glycine)   seen   in   advanced   KrasG12D;;p53-­/-­   lung   tumours   [21]   suggests   that   efficient  
antioxidant  strategies  may  be  actively  selected  for  within  this  genotype,  which  in  turn  could  
diminish  the  potential  effect  of  antioxidant  treatment  in  these  tumours.    
Data  from  human  NSCLC  reinforces  the  notion  that  enhanced  ROS  management  is  positively  
selected  during  lung  tumour  progression  (Figure  3).  Mutations  in  KEAP1,  a  NRF2  inhibitor  are  
present  in  ~20%  of  human  lung  adenocarcinomas  [33].  Moreover,  NRF2  signalling  was  shown  
to  regulate  the  expression  of  serine  biosynthesis  genes  in  human  NSCLC  cells  and  enhanced  
expression  of   these  genes  correlated  with  poor  overall  survival   [74],  suggesting   that  NRF2  
activity  may  directly  contribute  to  lung  cancer  malignant  progression.    
It  is  unclear  whether  improved  ROS  management  contributes  to  tumour  progression  by  simply  
increasing   cellular   fitness/survival   under   high   ROS   conditions   [75-­77]   or   through   other  
mechanisms.   Studies   in   melanoma   showed   that   cells   in   the   blood   and   visceral   organs  
experience  increased  levels  of  oxidative  stress  relative  to  established  subcutaneous  tumours  
[78].  Metastatic  cells  may  therefore  need  to  be  able  to  cope  with  high  ROS  levels  and  thus,  
improved   ROS   management   may   increase   the   metastatic   potential   of   tumour   cells.   In  
agreement,  p53-­null;;KrasG12D/G12D  lung  tumour  cells,  which  showed  lower  ROS  and  increased  
antioxidant  capacity   relative   to  heterozygous  cells,  were  more  metastatic   in   transplantation  
assays   than  p53-­null;;KrasG12D/+  cells   [21].  Notably,   in  other  contexts,   increased  ROS  levels  
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were  shown  to  promote  metastasis  [79-­81],  suggesting  that  altered  redox  management  may  
provide  distinct  benefits  to  different  cells.    
Interestingly,  the  ROS  levels  of  mutant  Kras  lung  tumours  can  vary  significantly  depending  on  
their  additional  driver  mutations  or  histological  subtype.  Accordingly,  in  KrasG12D/+;;Lkb1-­/-­  mice,  
ROS   levels   were   shown   to   increase   during   lung   adenocarcinoma   progression,   and   the  
corresponding  adenocarcinomas  exhibited  significantly  higher  ROS   levels,   than   those   from  
KrasG12D/+;;p53-­/-­   animals   [53].   Expression   of   Nrf2   and   its   target   Nqo1   were   conversely  
significantly   lower   in   Lkb1-­deficient   adenocarcinomas   relative   to   p53-­/-­.   Besides  
adenocarcinomas,  KrasG12D/+;;Lkb1-­/-­   animals   also   develop   lung   squamous   cell   carcinomas  
(SCC)  and  adeno-­squamous  cell  carcinomas  and  remarkably,  ROS  levels  were  significantly  
lower  in  SCC  relative  to  adenocarcinomas.  These  data  suggest  that  changes  in  ROS  levels  
can  modulate  adenocarcinoma  to  SCC  transdifferentiation,  and  this  plasticity  can  potentially  
affect  therapeutic  responses.    
Collectively,   the  abovementioned  studies  show  that   redox  management  plays  an   important  
role   in   mutant   KRAS   lung   cancer,   potentially   modulating   progression   mechanisms   and  
therapeutic  responses.  
Targeting  the  metabolism  of  mutant  Kras  lung  tumours  
As  mutant  Kras  remains  clinically  undruggable  and  its  prognostic  value  in  lung  cancer  unclear,  
the  status  of  this  locus  in  lung  tumours  is  not  even  routinely  assessed  outside  the  clinical  trial  
setting  [42].  Recent  progress  regarding  the  targeting  of  the  G12C  mutant  KRAS  isoform  with  
small  molecule  inhibitors  has  renewed  hope  that  the  clinical  relevance  of  mutant  KRAS  status  
may  soon  change  [82,  83].  If  indeed  effective,  these  inhibitors  will  be  of  particular  interest  for  
the  treatment  of  lung  adenocarcinoma,  where  G12C  is  the  most  frequent  KRAS  mutation  [84].  
The  recently  described  metabolic  phenotypes  of  mutant  Kras   tumours  provide  a  novel  and  
appealing  alternative  targeting  opportunity.  Metabolic  targeting  strategies  that  have  been  pre-­
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clinically  validated  in  lung  models  are  discussed  below  and  summarised  in  Figure  4.    
Reassuringly,   mouse   models   suggest   that   targeting   liabilities   inherent   to   mutant   KRAS  
metabolic   rewiring  may   constitute   a   feasible   “synthetic   lethal”   approach.  The  high   glucose  
dependence  of  advanced  mutant  Kras  lung  tumours  is  a  major  area  of  interest.  Due  to  their  
reliance  on  glucose  metabolism  for  enhanced  antioxidant  potential,  high  grade  lung  tumours  
from  KrasG12D/+;;p53Fx/Fx  mice  showed  a  high  sensitivity  to  combined  glucose  and  glutathione  
depletion  [21].  The  same  treatment  had  no  significant  effect  on  low  grade  tumours  of  the  same  
model,  where  glucose  metabolism  was  more  comparable  to  that  of  normal  tissues.  While  this  
heterogeneity  is  not  ideal  from  a  tumour-­response  perspective,  it  indicates  that  there  is  likely  
a  therapeutic  window  for  targeting  glucose  metabolism  rewiring  in  these  tumours  when  normal  
tissue  can  be  spared.  Importantly,  since  this  rewiring  was  associated  with  high  grade  tumours,  
these  therapeutic  strategies  have  the  potential  to  target  a  significant  proportion  of  human  lung  
tumours,  as  these  are  typically  diagnosed  late.    
Glucose   depletion  may   nevertheless   pose   significant   toxicity   risks   in   the   clinic.   Instead,   a  
better   efficiency   to   tumour   specificity   balance   may   be   achieved   through   the   targeting   of  
tumour-­specific  phenotypes  associated  with  this  metabolic  reprogramming.  Multiple  glycolytic  
genes   are   upregulated   in   lung   adenocarcinoma,   representing   potential   targets,   including  
Glucose  transporter  type  1  (SLC2A1  or  GLUT1),  Phosphoglycerate  kinase  1  (PGK1),  Enolase  
(ENO1),  Phosphofructokinases  (PFKL/PFKM),  Glyceraldehyde-­3-­Phosphate  Dehydrogenase  
(GAPDH),  Pyruvate  kinase  (PKM2)  and  lactate  dehydrogenase  (LDH).  Given  that  increased  
expression  of  SLC2A1,  PGK1,  ENO1,  GAPDH  and  PKM2  correlate  with  poor  prognosis  [85-­
89],   inhibition   of   these   proteins   may   be   particularly   beneficial.   In   agreement,   inhibition   of  
SLC2A1  and  PKM2  showed  promising  results  in  NSCLC  cells  in  vitro  and  xenograft  models  
[90-­92].    
Hexokinase  2  (Hk2)  knockout  models  suggest  that  the  inhibition  of  this  key  glycolytic  enzyme  
may  also  provide  therapeutic  benefit  to  mutant  Kras  lung  tumours.  Accordingly,  tumour  latency  
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of  KrasG12D/+  mice  was  increased  upon  Hk2  loss  [93],  while  systemic  ablation  of  Hk2  decreased  
the  proliferation  of  established  KrasG12D-­driven  lung  tumours.  The  conversion  of  pyruvate  to  
lactate  by  Ldh  enzymes  has  also  been  targeted  in  vivo  in  spontaneous  KrasG12D-­driven  lung  
tumours   [94].   Ldha   depletion   or   inhibition   resulted   in   decreased   tumourigenesis   and  
regression   of   established   lesions,   suggesting   a   role   for   Ldha   in   tumour   initiation   and  
proliferation.   Interestingly,   the   main   metabolic   changes   observed   in   vivo   were   decreased  
lactate  fermentation  and  glutathione  synthesis,  suggesting  that  either  or  both  metabolites  are  
relevant  for  tumour  initiation.    
Oxidative  pathways  represent  additional  opportunities  for  lung  cancer  targeting.  In  light  of  the  
effects  of  autophagy  inhibition  on  mitochondrial  functionality  and  tumour  maintenance  [64,  95]  
(discussed   above),   the   direct   targeting   of   mitochondrial   activity   may   be   therapeutically  
relevant.   In   agreement,   phenformin,   a  mitochondrial   complex   I   inhibitor   showed   promising  
(albeit  genotype-­specific)  therapeutic  efficacy,  decreasing  tumour  burden  in  KrasG12D/+;;Lkb1-­/-­  
mice  (but  not  in  KrasG12D/+;;p53-­/-­)  [96].  Moreover,  tissue-­specific  deletion  of  the  mitochondrial  
transcription   factor   A   (Tfam),   which   is   required   for   mitochondrial   DNA   replication   and  
transcription,  inhibited  lung  tumour  formation  and  growth  in  KrasG12D/+  mice  [72].  The  multiple  
mutant  Kras  pre-­clinical  models  discussed  above  demonstrate  that  mutant  Kras  tumours  also  
exhibit   unique   dependences   regarding   fatty   acid   synthesis   and   oxidation,   TCA-­dependent  
glucose   metabolism,   and   branched-­chain   amino   acid   utilization,   which   can   potentially   be  
exploited  therapeutically  [21,  25,  61,  62,  64].  
While   the   unique   metabolic   vulnerabilities   of   mutant   KRAS   tumours   represent   important  
opportunities  for  therapeutic  targeting,  their  metabolic  heterogeneity  can  potentially  influence  
therapeutic   responses   beyond   direct  metabolic   targeting.   Hence,   it   would   be   important   to  
determine   to   what   extent   lung   tumour   metabolic   heterogeneity   may   affect   the   efficacy   of  
standard  therapy  and  subsequently,  whether  it  can  be  involved  in  resistance  to  conventional  
cancer  treatments.  
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The  tumour  microenvironment  perspective  
Data   from   different   groups   point   to   significant  metabolic   heterogeneity   within  mutant   Kras  
tumours.   This   heterogeneity   is   seen   between   mutant   Kras   tumours   from   different   tissues  
(pancreatic  and  lung  tumours  of  a  comparable  genotype)  [25];;  lung  tumours  in  vivo  and  their  
corresponding  cell   lines   in  vitro  [57];;  and  low  and  high  grade  lung  tumours  within  the  same  
model   [21].   While   some   of   this   metabolic   variation   may   be   tumour   cell   autonomous,  
microenvironmental  factors  are  likely  important  players  in  this  heterogeneity.  	  
The  tumour  microenvironment  is  now  increasingly  recognised  as  a  crucial  element  in  tumour  
development,  maintenance   and   response   to   therapy.   The   lung   tumour   stroma   consists   of  
multiple   non-­cancerous   cells,   such   as   immune   cells   and   fibroblasts,   which   can   provide  
structural  support,  but  also  immune  protection  and  even  promote  invasion  and  metastasis  [50,  
97].   Stromal   cells   can   affect   tumour   cell   metabolism   through   a   plethora   of   mechanisms,  
including  competition   for  nutrients   [98];;  provision  of  alternative  metabolic  substrates   [99]  or  
modulation  of  tumour  cell  signalling  via  cell  to  cell  contacts  [98-­100].  This  interplay  between  
stroma   and   tumour   cells   can   thus   potentially   contribute   another   layer   of   complexity   and  
heterogeneity   to   tumour  metabolism,  but   it   remains  poorly  studied   in   the  context  of  mutant  
Kras  lung  tumours.    
The  tumour  microenvironment  is  also  of  relevance  from  a  lung  tumour  therapy  perspective.  
Indeed,  there  is  strong  evidence  that  targeting  the  tumour-­stroma  crosstalk  can  be  beneficial  
for   lung  cancer  patients,  with   immune  checkpoint   inhibitors   (anti-­PD-­L1,  anti-­PD-­1)  already  
showing   therapeutic  promise   in  advanced  NSCLC  [101-­103].  However,   resistance   to   these  
checkpoint  antagonists  has  also  been  reported  and  the  potential  effects  of  tumour  metabolism  
heterogeneity   should   be   considered   in   this   context.   For   instance,   since   altered  metabolic  
programs  can  affect  T-­cell  fate  and  differentiation  [104,  105],  tumours  with  distinct  metabolic  
properties   can   potentially  modulate   T-­cell   responses   differently   ([106-­108]),   increasing   the  
likelihood  of  resistance  to  treatment.  Likewise,  agents  that  target  tumour  cell  metabolism  may  
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yield  unexpected  results  due  to  their  potential  effects  on  stroma  cells  and  stroma-­tumour  cell  
communication.  In  vivo  models  will  likely  prove  invaluable  in  the  evaluation  of  stromal  effects  
on  metabolic  targeting  and  resistance  to  therapy  in  lung  tumours.    
Closing  remarks    
The  development  of  tools  that  enable  the  analysis  of  metabolic  flux  in  vivo  revolutionised  the  
cancer  metabolism  field.  Rather  than  a  simplistic,  unified  model,  we  are  now  confronted  with  
tumours  as  evolving  metabolic   entities,  where  both  general   and   context-­specific  metabolic  
requirements   need   to   be   considered.   This   metabolic   heterogeneity   may   in   fact   have  
contributed   to   differential   therapeutic   responses   in   seemingly   comparable   tumours,  
confounding   our   assessments   of   their   efficacy.   Despite   this   intrinsic   heterogeneity,   the  
therapeutic  potential  of  metabolic  targeting  remains  high,  as  demonstrated  in  the  multiple  in  
vivo  mutant  Kras  lung  tumour  studies  discussed  here.  Improved  understanding  of  the  unique  
metabolic  dependencies  of  lung  tumours   in  vivo  is  essential  for  the  design  of  therapies  that  
efficiently  target  this  heterogeneous  and  evolving  disease.  By  exposing  such  novel  and  much  
needed  vulnerabilities  in  the  large  proportion  of  NSCLC  affected  by  KRAS  mutations  we  may  
finally  be  able  to  change  the  course  of  this  often  deadly  disease.  
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Figure  legends  
Figure  1:  Human  NSCLC  metabolism  based  on  in  situ  glucose  flux  analysis.  
Representation   of   glucose-­derived   carbon   flux   in   human   NSCLC   following   13C-­glucose  
infusion  [23,  27,  28].  Metabolites  referred  to  in  the  main  text  (*),  as  well  as  others  discussed  
in   the   references   are   indicated.   Enhanced   glucose   metabolism   (orange)   and   alternative  
pathway  fuels  (purple)  are  shown.  PDH,  pyruvate  dehydrogenase;;  PC,  pyruvate  carboxylase.  
  
Figure  2:  Metabolic  rewiring  in  lung  tumours  from  KrasG12D/+;;  p53-­/-­  mice.  
Schematic  representation  of  metabolic  networks  in   lung  tumours  from  KrasG12D/+;;p53-­/-­  mice  
based   on   in   vivo   flux/tracing   analyses.   Enhanced   flux   from  different   labelled   substrates   is  
shown  as   indicated,  with  orange  depicting  glucose  metabolism  (based  on  13C-­Glucose  [21,  
57]);;  green:  amino  acid  metabolism  (13C-­Leucine/Valine;;  solid),  15N-­Leucine;;  dashed  [25]);;  and  
purple:   fatty  acid  metabolism  (2H2O  [62]).  Grey  arrow  depicts  similar   flux   relative   to  normal  
tissue   [57].   Slc2a1,   Glucose   transporter   1;;   Acc,   Acetyl-­Co   A   carboxylase;;   Gcs,  
glutamylcysteine  synthetase;;  Pdh,  pyruvate  dehydrogenase;;  Pc,  pyruvate  carboxylase.  
  
Figure   3:   Metabolic   reprogramming   during   mutant   Kras-­driven   lung   tumour  
progression.  
Representation  of  cellular  phenotypes  altered  during  the  progression  of  low  (adenoma,  Grade  
I  and  II  adenocarcinoma)  to  high  grade  (Grade  III  and  IV  adenocarcinoma)  lung  tumours  in  
KrasG12D/+;;p53-­/-­  mice.    
  
Figure  4:  Metabolic  targets  of  mutant  Kras  lung  tumours  validated  in  vivo.  
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Schematic  representation  of  metabolic  targeting  strategies  that  showed  therapeutic  efficacy  
in  spontaneous  mutant  Kras  lung  tumours  (GEMM  KO  and/or  pharmacologic  inhibition  (*))  or  
NSCLC  cell  line  xenografts.  Metabolites  and  enzymes  are  shown,  with  genes  overexpressed  
in  human  NSCLC  samples  indicated  in  red.  Targeting  approach  and  method  of  inhibition  are  
shown   in   blue.   ETC:   Electron   Transport   Chain;;   2DG:   2-­deoxyglucose;;   BSO:   Buthionine  
Sulfoximine;;   GEMM   KO:   Genetically   engineered   mouse   model   knock-­out;;   CRISPR   KO:  
Clustered   regularly   interspaced   short   palindromic   repeats   knock-­out;;   shRNA:   short-­hairpin  
RNA;;  SMI:  Small  molecule  inhibitor.  
  




